Cullinan Oncology Significantly Increases Ownership Stake in its MICA Subsidiary which Holds Worldwide Rights to Clinical-Stage Novel Monoclonal Antibody CLN-619

October 25, 2022

https://www.globenewswire.com/news-release/2022/10/25/2540655/0/en/Cullinan-Oncology-Significantly-Increases-Ownership-Stake-in-its-MICA-Subsidiary-which-Holds-Worldwide-Rights-to-Clinical-Stage-Novel-Monoclonal-Antibody-CLN-619.html

Cullinan increases ownership in MICA subsidiary from 54% to 92% through share purchase from existing financial investors

The ongoing Phase I clinical trial for CLN-619 remains on track to report initial clinical data in mid-2023

Read more at globenewswire.com

Related news for (CGEM)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.